HTA Glossary
Incremental cost-effectiveness ratio (ICER)
The incremental cost-effectiveness ratio (ICER) is the extra cost of one health technology compared with another, divided by the extra health benefit it produces. It is usually expressed as a cost per quality-adjusted life year (QALY) gained and is set against a willingness-to-pay threshold to judge value for money.
By HTA Course · Last reviewed
In more detail
ICER explained
A hypothetical example: a new medicine costs £30,000 more per patient than standard care and yields 1.5 more QALYs. Its ICER is £30,000 divided by 1.5, or £20,000 per QALY gained.
An ICER always describes a comparison, never a technology on its own. Change the comparator and the ratio changes, so the choice of comparator is one of the most contested points in any assessment.
The ratio is informative only when the new technology is both more effective and more costly, or both less effective and less costly. If it is more effective and cheaper it dominates the comparator, and no ratio is needed. Negative ICERs are hard to interpret and are generally not reported, because the same negative number can describe a clearly better option and a clearly worse one.
The abbreviation has a second meaning: ICER is also the Institute for Clinical and Economic Review, an independent US body that assesses the value of medicines.
Formula
ICER formula
Effects are usually measured in QALYs, so the result reads as cost per QALY gained.